Gilead Sciences and Scholar Rock have formed a collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases.
Finland-based DelSiTech and Mexican pharma company Innovare R&D have signed a world-wide, exclusive license agreement for the use of the former’s Silica Matrix drug delivery platform in the development and commercialization of a long acting HIV therapy.
Amgen and Molecular Partners have announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB).
Japan-based Fuji Pharma has acquired a 4.2% stake in biopharmaceutical firm Alvotech for around $50m.
C4X Discovery (C4XD) and UK-based gene editing company Horizon Discovery Group have forged an exclusive target discovery partnership in oncology.
Incyte and Innovent Biologics have entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Incyte.
Bausch Health Companies has signed an agreement to acquire certain assets of Synergy Pharmaceuticals in a transaction valued at around $200m plus certain assumed liabilities.
Eli Lilly and Company (Lilly) and AC Immune have signed a license and collaboration agreement, potentially worth around CHF1.89bn ($1.9bn), for research and development of tau aggregation inhibitor small molecules for the treatment of neurodegenerative diseases like Alzheimer’s disease (AD).
AMAG Pharmaceuticals has signed an agreement to acquire US-based private biopharmaceutical firm Perosphere Pharmaceuticals.
X-Chem and Almirall have partnered to discover lead compounds for innovative and challenging targets with dermatology applications.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.